Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Escient Pharmaceuticals
Biotech
Incyte's $750M buyout rocked by pause on key trial, asset cull
Less than six months after closing the deal, Incyte has paused a key study over preclinical toxicology findings and axed another program altogether.
Nick Paul Taylor
Nov 19, 2024 4:12am
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Apr 23, 2024 10:43am
Sanofi-backed Escient bags $120M series C
Nov 28, 2022 11:06am
Sanofi backs Escient as it kick-starts first clinical test
Sep 15, 2020 8:15am